Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,208.12 +80.43 (+7.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
News headline image
Dow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh" ↗
Markets opened lower on Iran fears and a Tesla stumble, but bounced back. Here's what investors need to know about Thursday's volatile session. 
Via The Motley Fool
Topics Government Stocks World Trade
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require... 
Via MarketMinute
Topics Economy
News headline image
Stock Market Rebounds Even As Oil Prices Skyrocket On Trump's Iran War Comments; Tesla, SpaceX, Eli Lilly In Focus: Weekly Review ↗
Tesla deliveries disappointed while Elon Musk's SpaceX filed for an IPO. 
Via Investor's Business Daily
Topics Government
News headline image
Stock Of The Day: Where Will Eli Lilly Turn? ↗
Eli Lilly (LLY) shares rallied after finding support at a formed resistance level. They may hit resistance at a former support level. 
Via Benzinga
News headline image
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience ↗
In a powerful demonstration of financial strength and strategic foresight, Eli Lilly and Company (NYSE: LLY) recently committed over $10 billion to two major initiatives in just a matter of days. While... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss Launch ↗
Novo Nordisk said Thursday a new study suggests patients prefer its oral Wegovy over Eli Lilly's new GLP-1 pill, Foundayo. 
Via Investor's Business Daily
News headline image
The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)
April 2, 2026 Introduction The Cigna Group (NYSE: CI) stands today at a pivotal crossroads, having undergone one of the most significant strategic transformations in the modern healthcare era. Long... 
Via Finterra
Topics Artificial Intelligence Economy Lawsuit
News headline image
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh ↗
Eli Lilly & Co shares are down Thursday despite FDA approval of its oral weight-loss drug Foundayo, as geopolitical tensions weigh on markets. 
Via Benzinga
News headline image
3 Monster Dividend Stocks to Hold for the Next 10 Years ↗
These are great and steady income providers for your portfolio. 
Via The Motley Fool
News headline image
Prediction: This Will Be Eli Lilly's Next Billion-Dollar Growth Driver. (Hint: It's Not Weight Loss Drugs.) ↗
Moves Lilly has recently made should support a new potential source of growth. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today ↗
GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026. 
Via Benzinga
News headline image
Why Eli Lilly Stock Trounced the Market Today ↗
Its first weight-loss pill was just approved by the FDA. 
Via The Motley Fool
News headline image
Stock Market Today, April 1: Markets Rally and Oil Prices Fall for Second Day Running ↗
Today, April 1, 2026, hopes that the Iran war may soon end drove markets upwards as tumbling oil prices reshaped the day’s winners. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Eli Lilly’s $47.8 Billion Masterstroke: The Contessa Acquisition and the New Era of Pharmaceutical Dominance
INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?
Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months. 
Via Barchart.com
News headline image
Could This New Approval Be a Turning Point For Novo Nordisk? ↗
The pharmaceutical giant still has plenty of work to do to recover from recent woes. 
Via The Motley Fool
News headline image
Why Is Eli Lilly Stock Gaining Today? ↗
Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market. 
Via Benzinga
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.7% in the afternoon session after the FDA approved Foundayo (orforglipro... 
Via StockStory
News headline image
Eli Lilly Jumps After Winning FDA Approval For Obesity Pill ↗
Eli Lilly stock jumped midday Wednesday after the FDA approved its weight-loss pill, now called Foundayo. 
Via Investor's Business Daily
News headline image
Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium ↗
Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones. 
Via Benzinga
News headline image
1 Reason This $900 Stock Could Announce a Split in 2026 ↗
This pharmaceutical giant appears well positioned for a potential stock split in 2026. 
Via The Motley Fool
News headline image
Hasbro's Q1 2026 Earnings: What to Expect
Hasbro is expected to announce its first-quarter results soon, and analysts are projecting a single-digit decline in its EPS. 
Via Barchart.com
Topics ETFs Workforce
News headline image
What to Expect From Nasdaq's Q1 2026 Earnings Report
Nasdaq will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth. 
Via Barchart.com
Topics ETFs Workforce
News headline image
Willis Towers Watson's Q1 2026 Earnings: What to Expect
Willis Towers Watson will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth. 
Via Barchart.com
Topics Artificial Intelligence ETFs Workforce
Wall Street Ends a Rough Quarter With Its Best Day, Iran Hope Ignites the Rally ↗
Via Chartmill
News headline image
Why Centessa Stock Soared Today ↗
A pharma giant wants to buy the innovative drug developer. 
Via The Motley Fool
News headline image
Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful? 
Via The Motley Fool
News headline image
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout ↗
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline. 
Via Benzinga
News headline image
Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?
Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market. 
Via Barchart.com
Topics Artificial Intelligence
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.